ACTON, Mass.--(BUSINESS WIRE)--Neuroptix Corporation, a Massachusetts-based pioneer in the early detection of Alzheimer’s disease through non-invasive laser eye scanning, today announced that it has successfully closed its Series A funding round, for a total of $1.6 million, to help further commercialize the company’s diagnostic platform.
